Francisca Vazquez

Dr. Francisca Vazquez


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Cell
Verified
Journal Article
Closed access
ATAviad Tsherniak
Aviad Tsherniak
FVFrancisca Vazquez
Francisca Vazquez
PMPhil G. Montgomery
Phil G. Montgomery
BWBarbara A. Weir
Barbara A. Weir
GKGregory Kryukov
Gregory Kryukov
WHWilliam C. Hahn
William C. Hahn

30 October 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RMRobin M Meyers
Robin M Meyers
JBJordan G Bryan
Jordan G Bryan
JMJames M McFarland
James M McFarland
BWBarbara A Weir
Barbara A Weir
ASAnn E Sizemore
Ann E Sizemore
ATAviad Tsherniak
Aviad Tsherniak
CERES is a new computational method to estimate gene-dependency levels from CRISPR–Cas9 essentiality screens while accounting for copy number effects and variable sgRNA activity. Applying CERES to new genome-scale CRISPR–Cas9 essentiality screen data from 342 cancer cell lines and other published data sets shows that CERES decreases false-positive results and provides consistent estimates of sgRNA activity. The CRISPR–Cas9 system has revolutionized gene editing both at single genes and in multiplexed loss-of-function screens, thus enabling precise genome-scale identification of genes essential for proliferation and survival of cancer cells1,2. However, previous studies have reported that a gene-independent antiproliferative effect of Cas9-mediated DNA cleavage confounds such measurement of genetic dependency, thereby leading to false-positive results in copy number–amplified regions3,4. We developed CERES, a computational method to estimate gene-dependency levels from CRISPR–Cas9 essentiality screens while accounting for the copy number–specific effect. In our efforts to define a cancer dependency map, we performed genome-scale CRISPR–Cas9 essentiality screens across 342 cancer cell lines and applied CERES to this data set. We found that CERES decreased false-positive results and estimated sgRNA activity for both this data set and previously published screens performed with different sgRNA libraries. We further demonstrate the utility of this collection of screens, after CERES correction, for identifying cancer-type-specific vulnerabilities.

1 December 2012 in Cell
Verified
Journal Article
Closed access
Joseph RosenbluhJoseph Rosenbluh
Joseph Rosenbluh
DNDeepak Nijhawan
Deepak Nijhawan
ACAndrew G. Cox
Andrew G. Cox
XLXingnan Li
Xingnan Li
JNJames T. Neal
James T. Neal
WHWilliam C. Hahn
William C. Hahn

11 March 2016 in Science
Verified
Journal Article
Closed access
PDF file
GKGregory V. Kryukov
Gregory V. Kryukov
FWFrederick H. Wilson
Frederick H. Wilson
JRJason R. Ruth
Jason R. Ruth
JPJoshiawa Paulk
Joshiawa Paulk
ATAviad Tsherniak
Aviad Tsherniak
LGLevi A. Garraway
Levi A. Garraway
Tumors put in a vulnerable position: Cancer cells often display alterations in metabolism that help fuel their growth. Such metabolic “rewiring” may also work against the cancer cells, however, by creating new vulnerabilities that can be exploited therapeutically. A variety of human tumors show changes in methionine metabolism caused by loss of the gene coding for 5-methylthioadenosine phosphorylase (MTAP). Mavrakis et al. and Kryukov et al. found that the loss of MTAP renders cancer cell lines sensitive to growth inhibition by compounds that suppress the activity of a specific arginine methyltransferase called PRMT5. Conceivably, drugs that inhibit PRMT5 activity could be developed into a tailored therapy for MTAP-deficient tumors. Science , this issue pp. 1208 and 1214

1 March 2013 in Cancer Cell
Verified
Journal Article
Closed access
FVFrancisca Vazquez
Francisca Vazquez
JLJi-Hong Lim
Ji-Hong Lim
HCHelen Chim
Helen Chim
KBKavita Bhalla
Kavita Bhalla
GGGeoff Girnun
Geoff Girnun
PPPere Puigserver
Pere Puigserver

17 September 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AGAndrew O. Giacomelli
Andrew O. Giacomelli
XYXiaoping Yang
Xiaoping Yang
RLRobert E. Lintner
Robert E. Lintner
JMJames M. McFarland
James M. McFarland
MDMarc Duby
Marc Duby
WHWilliam C. Hahn
William C. Hahn